> Detailanzeige

Strobel, Oliver; Lorenz, Philipp; Hinz, Ulf; Gaida, Matthias; König, Anna-Katharina; Hank, Thomas; Niesen, Willem; Kaiser, J.ö.rg; Al-Saeedi, Mohammed; Bergmann, Frank; Springfeld, Christoph; Berchtold, Christoph; Diener, Markus K.; Schneider, Martin; Mehrabi, Arianeb; Müller-Stich, Beat P.; Hackert, Thilo; Jager, Dirk; Büchler, Markus W.

Actual Five-year Survival After Upfront Resection for Pancreatic Ductal Adenocarcinoma : Who Beats the Odds?

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Actual Five-year Survival After Upfront Resection for Pancreatic Ductal Adenocarcinoma : Who Beats the Odds? : Who Beats the Odds?
  • Beteiligte: Strobel, Oliver; Lorenz, Philipp; Hinz, Ulf; Gaida, Matthias; König, Anna-Katharina; Hank, Thomas; Niesen, Willem; Kaiser, J.ö.rg; Al-Saeedi, Mohammed; Bergmann, Frank; Springfeld, Christoph; Berchtold, Christoph; Diener, Markus K.; Schneider, Martin; Mehrabi, Arianeb; Müller-Stich, Beat P.; Hackert, Thilo; Jager, Dirk; Büchler, Markus W.
  • Erschienen: Ovid Technologies (Wolters Kluwer Health), 2022
  • Erschienen in: Annals of Surgery, 275 (2022) 5, Seite 962-971
  • Sprache: Englisch
  • DOI: 10.1097/sla.0000000000004147
  • ISSN: 0003-4932; 1528-1140
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:sec> <jats:title>Objective:</jats:title> <jats:p>To determine actual five-year survival (5YS) rates associated with a strategy of upfront surgery and adjuvant therapy in pancreatic ductal adenocarcinoma (PDAC).</jats:p> </jats:sec> <jats:sec> <jats:title>Background:</jats:title> <jats:p>The rate of actual 5YS in PDAC remains controversial. Available data is restricted to cohorts acquired over several decades and series of resection after patient selection by neoadjuvant therapy.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods:</jats:title> <jats:p>All patients undergoing upfront resection for resectable and borderline-resectable PDAC from 10/2001 to 12/2011 were identified from a prospective database. Actual overall survival was assessed after a follow-up of at least 5 years. Uni- and multivariable logistic regression analyses were performed.</jats:p> </jats:sec> <jats:sec> <jats:title>Results:</jats:title> <jats:p>Median survival of 937 patients was 22.1 months. The actual 5YS rate was 17.0% (n = 159) including 89 (9.5%) patients without evidence of disease &gt;5 years after resection. 5YS rates in patients with or without adjuvanttherapy were 18.8% vs. 12.2%, respectively. Tumorgrading, number of positive lymph nodes, a context of intraductal papillary mucinous neoplasia, and vascular resections were independently associated with 5YS. Patient-related parameters and CA 19-9 levels were associated with observed survival up to 3 years, but lost relevance thereafter. The extent of lymph node involvement was the strongest predictor of 5YS. Patients with pN0R0 had a 5YS rate of 38.2%. in patients with exclusively favorable factors the observed 5YS rate was above 50%.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions:</jats:title> <jats:p>This is the largest series of long-term survivors with histologically confirmed PDAC. With upfront resection and adjuvant therapy an actual overall 5YS rate of 18.8% can be expected. in favorable subgroups actual 5YS is above 50%.</jats:p> </jats:sec>